Prosecution Insights
Last updated: November 04, 2026

Principia Biopharma Inc.

Technology area: Biotechnology & Pharmaceuticals

7 pending office actions • 6 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days

Analysis

Principia Biopharma Inc. manages 7 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 6 distinct art units and 7 distinct examiners. This ratio of examiners to actions indicates that each pending matter is being handled by a different individual, preventing a concentration of the workload. The 7 pending office actions are thus subject to 7 different sets of examiner preferences.

The busiest examiner, COLEMAN, BRENDA LIBBY, is responsible for 1 pending office action. With 7 distinct examiners involved, the prosecution strategy must account for a range of individual examiner approaches. The involvement of 6 distinct art units suggests that the company's research is being evaluated by several different specialized groups. This diversity in examination requires a highly individualized approach to each of the 7 pending office actions currently in the portfolio within the Biotechnology & Pharmaceuticals technology area.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

7
Total Pending OAs
6
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
0
Due this month
1
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (29%)
3
Medium (43%)
2
Easy (29%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only2 (29%)
§112 only2 (29%)
Double-patenting + other1 (14%)
Multi-statute (no §101)2 (29%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

7
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

70 h
Manual time on pending OAs
14 h
Time saved (low, 20%)
24 h
Time saved (mid, 35%)
0.6 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
COLEMAN, BRENDA LIBBY 1 74.8% +15.7%
MERCIER, MELISSA S 1 72.1% +5.7%
HERNANDEZ, JACKSON J 1 50.7% +40.5%
FETTEROLF, BRANDON J 1 51.8% +18.6%
RODRIGUEZ-GARCIA, VALERIE 1 68.9% +31.7%
RZECZYCKI, PHILLIP MATTHEW 1 65.4% +36.8%
HUI, SAN MING R 1 59.6% +20.1%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18789827 PROCESS OF MAKING 2-[(3R)-2-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4[4-(OXETAN-3-YL)PIPERAZIN-1-YL]-PENT-2-ENENITRILE AND SOLVATE FORMS THEREOF HERNANDEZ, JACKSON J —
18377540 THERAPEUTIC TYROSINE KINASE INHIBITORS FOR MULTIPLE SCLEROSIS RODRIGUEZ-GARCIA, VALERIE —

Interview Candidates (6)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.

App #TitleExaminerDue in
17920147 Treatment of Acute Respiratory Distress Syndrome and Other Disorders Involving Cytokine Storm Using BTK Inhibitors RZECZYCKI, PHILLIP MATTHEW 53d
18864343 THERAPEUTIC TYROSINE KINASE INHIBITORS FOR MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY DISEASE (MOGAD) COLEMAN, BRENDA LIBBY —
18789827 PROCESS OF MAKING 2-[(3R)-2-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4[4-(OXETAN-3-YL)PIPERAZIN-1-YL]-PENT-2-ENENITRILE AND SOLVATE FORMS THEREOF HERNANDEZ, JACKSON J —
18756019 METHODS FOR TREATING PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA IN CHILDREN, ADOLESCENTS AND ADULTS BY ADMINISTERING (R)-2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENENITRILE FETTEROLF, BRANDON J —
18377540 THERAPEUTIC TYROSINE KINASE INHIBITORS FOR MULTIPLE SCLEROSIS RODRIGUEZ-GARCIA, VALERIE —
17957073 Method of Treating Pemphigus by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-Enenitrile HUI, SAN MING R —

Top Art Units

Art UnitApps
1627 2
1624 1
1615 1
1626 1
1621 1
1625 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18864343 THERAPEUTIC TYROSINE KINASE INHIBITORS FOR MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY DISEASE (MOGAD) COLEMAN, BRENDA LIBBY 1624 §112 Non-Final OA — Pending Nov 08, 2024
18889671 Topical Pharmaceutical Compositions Comprising 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4,4-Dimethylpent-2-Enenitrile MERCIER, MELISSA S 1615 §112 Non-Final OA — Pending Sep 19, 2024
18789827 PROCESS OF MAKING 2-[(3R)-2-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4[4-(OXETAN-3-YL)PIPERAZIN-1-YL]-PENT-2-ENENITRILE AND SOLVATE FORMS THEREOF HERNANDEZ, JACKSON J 1627 §103§112Other Non-Final OA — Pending Jul 31, 2024
18756019 METHODS FOR TREATING PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA IN CHILDREN, ADOLESCENTS AND ADULTS BY ADMINISTERING (R)-2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENENITRILE FETTEROLF, BRANDON J 1626 §102§103DP Non-Final OA — Pending Jun 27, 2024
18377540 THERAPEUTIC TYROSINE KINASE INHIBITORS FOR MULTIPLE SCLEROSIS RODRIGUEZ-GARCIA, VALERIE 1621 §103§112 Non-Final OA — Pending Oct 06, 2023
17920147 Treatment of Acute Respiratory Distress Syndrome and Other Disorders Involving Cytokine Storm Using BTK Inhibitors RZECZYCKI, PHILLIP MATTHEW 1625 §103 Final Rejection 53d Pending Oct 20, 2022
17957073 Method of Treating Pemphigus by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-Enenitrile HUI, SAN MING R 1627 §103 Non-Final OA — Pending Sep 30, 2022

Managing Principia Biopharma Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Principia Biopharma Inc. have?

Principia Biopharma Inc. has 7 pending office actions as of November 2026, spread across 6 art units and 7 examiners.

Which USPTO examiner handles the most Principia Biopharma Inc. applications?

Brenda Libby Coleman has the most, with 1 of Principia Biopharma Inc.'s pending office actions.

What technology area are Principia Biopharma Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month